通过参考类别绘制和报告异质性治疗效果
在随机对照试验中探索异质性治疗效果是精准医学的重要方面,但预测模型易过拟合和多重检验。本文提出两阶段方法:先基于基线协变量估计风险评分,再沿该轴通过重加权探索异质性,避免多重检验并保留原始结局尺度。以重症恶性疟疾最大随机试验为例,显示绝对死亡率风险降低在高风险层显著增加。
要点
- 两阶段法避免多重检验,保留原始结局尺度。
- 风险评分单维概括异质性,重加权探索效果。
- 高风险层绝对死亡率风险降低更明显。
核心结论
- 基于基线风险排序的局部和倾斜重加权方案可作为探索、绘制和报告随机对照试验中异质性治疗效果的通用方法。
研究设计与样本
- 方法学文章,提出两阶段法:先估计风险评分,再沿风险轴重加权探索异质性。
- 案例研究使用重症恶性疟疾最大随机治疗试验(ISRCTN50258054)。
主要发现
- 在重症恶性疟疾试验中,绝对死亡率风险降低在高风险层显著增加。
临床怎么用
- 可用于多变量基线风险模型,评估平均治疗效果对研究人群风险分布的稳定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exploration and modelling of heterogeneous treatment effects as a function of baseline covariates is an important aspect of precision medicine in randomised controlled trials (RCTs). Randomisation generally guarantees the internal validity of an RCT, but heterogeneity in treatment effect can reduce external validity. Estimation of heterogeneous treatment effects is usually done via a predictive model for individual outcomes, where one searches for interactions between treatment allocation and important patient baseline covariates. However, such models are prone to overfitting and multiple testing and typically demand a transformation of the outcome measurement, for example, from the absolute risk in the original RCT to log-odds of risk in the predictive model. METHODS: We show how reference classes derived from baseline covariates can be used to explore heterogeneous treatment effects via a two-stage approach. We first estimate a risk score which captures on a single dimension some of the heterogeneity in outcomes of the trial population. Heterogeneity in the treatment effect can then be explored via reweighting schemes along this axis of variation. This two-stage approach bypasses the search for interactions with multiple covariates, thus protecting against multiple testing. It also allows for exploration of heterogeneous treatment effects on the original outcome scale of the RCT. This approach would typically be applied to multivariable models of baseline risk to assess the stability of average treatment effects with respect to the distribution of risk in the population studied. CASE STUDY: We illustrate this approach using the single largest randomised treatment trial in severe falciparum malaria and demonstrate how the estimated treatment effect in terms of absolute mortality risk reduction increases considerably in higher risk strata. CONCLUSIONS: 'Local' and 'tilting' reweighting schemes based on ranking patients by baseline risk can be used as a general approach for exploring, graphing and reporting heterogeneity of treatment effect in RCTs. TRIAL REGISTRATION: ISRCTN clinical trials registry: ISRCTN50258054. Prospectively registered on 22 July 2005.
引用
- Watson JA, Holmes CC. Graphing and reporting heterogeneous treatment effects through reference classes. Trials. 2020. PMID: 32381030. doi:10.1186/s13063-020-04306-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。